



A Quick Look at Using Meningococcal Vaccines

Ages 6 Weeks through 10 Years

Age Indications for Each Brand

MenHibrix® (Hib-MenCY): Ages 6 weeks through 18 months
Menveo® (MenACWY-CRM): Ages 2 months through 55 years
Menactra® (MenACWY-D): Ages 9 months through 55 years

Recommended Schedule

- Vary by age and risk condition

Indication for Use

- MenHibrix is recommended for infants at high risk for meningococcal disease and who also need a routine Hib vaccine; contains protection against serotypes C, Y
- Menactra and Menveo contain protection against serotypes A, C, W, Y

Minimum interval

- Varies by brand, risk group and age at time of vaccination

Vaccine Administration

- Intramuscular (IM) injection in deltoid or anterolateral thigh
 - 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting site and needle length
- Give simultaneously with all vaccines

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8° C)
 - Stand-alone storage units are preferred
- Do not freeze; Keep in the original box
- Menactra is ready to use; shake well
- Reconstitute Menveo & MenHibrix
 - Menveo: draw up MenCYW liquid (diluent); add to Men A vial; invert and shake well
 - MenHibrix: use saline diluent packaged with vaccine; draw up entire vial (0.85mL); Administer within 30 min

CHILDREN AGED 6 WEEKS-10 YEARS WHO ARE AT INCREASED RISK FOR MENINGOCOCCAL DISEASE

- Children with anatomic or functional asplenia (including sickle cell disease):
 - For children younger than age 19 months, give a 4-dose series of MenHibrix or Menveo at age 2, 4, 6, & 12-15 months
 - For children aged 19 through 23 months who have not completed a series of MenHibrix or Menveo, administer 2 primary doses of Menveo at least 3 months apart.
 - For children aged 24 months & older who have not received a complete series of MenHibrix, Menveo or Menactra, give 2 primary doses of either Menactra or Menveo at least 2 months apart.
 - o Due to interference between the 2 vaccines, do not give Menactra prior to completing the Pneumococcal Conjugate Vaccine (PCV13) series; wait at least 4 weeks after the PCV13 series to give Menactra; Menveo can be given with PCV13
 - Booster dose for children: aged less than 7 years - in 3 years then every 5 years; aged 7 years or older - every 5 years
- Children with persistent complement component deficiency:
 - For children younger than age 19 months, give a 4-dose series of either MenHibrix or Menveo at age 2, 4, 6, & 12-15 months
 - For children aged 7 through 23 months who have not begun vaccination, 2 options exist depending on age & vaccine brand:
 - o For children who began vaccination with Menveo at 7 months through 23 months of age, a 2-dose series should be administered with the second dose after 12 months of age and at least 3 months after the first dose.
 - o For children who began vaccination with Menactra at 9 months through 23 months of age, a 2-dose series of Menactra should be administered at least 3 months apart.
 - For children aged 24 months & older who have not received a complete series of MenHibrix, Menveo, or Menactra, administer 2 primary doses of either Menactra or Menveo at least 2 months apart¹
 - Booster dose for children: aged less than 7 years - in 3 years then every 5 years; aged 7 years or older - every 5 years
- Children who travel to or reside in countries with high risk for meningococcal disease (i.e., African meningitis belt or the Hajj):
 - Administer age-appropriate dose(s) of Menactra or Menveo (contain serotypes A, W needed for travel)²
- Children at risk during a community outbreak due to serotype A, C, W, Y
 - Administer or complete an age- and formulation-appropriate vaccine (refer to "Indications for Use")²

CONTRAINDICATIONS

- Menactra or Menveo: An anaphylactic (severe allergic) reaction to a prior dose or a component of meningococcal vaccine
- MenHibrix: An anaphylactic reaction to prior dose or component of meningococcal, Hib or tetanus-toxoid containing vaccines

PRECAUTIONS

- Moderate to severe acute illness with or without fever

FURTHER POINTS

- Meningococcal Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
- Document Menactra as "MCV4 (Menactra)", Menveo as "MCV4 (Menveo)", and MenHibrix as Hib-MenCY (MenHibrix) in MCIR
- Document as MenACWY (Menactra) or MenACWY (Menveo) or Hib-MenCY on immunization record card and/or chart or EMR
- Use the lot number on the outside box of Menveo to document in MCIR and on the vaccine record

¹Children indicated for a 2-dose primary series who previously received only 1 dose of MenACWY, should get a 2nd dose of MenACWY as soon as feasible; forecast for the booster dose (if applicable) from the date of the 2nd primary series dose

²Children aged 24 months & older with HIV and an indication for vaccination: If no previous complete series, give a 2-dose primary series (0, 2 mo)